TLR7 and neoplasm: Recently, Kim et al. (2019) reported that TLR7/8 agonists-loaded NEs along with tumor antigens effectively induced antitumor immune response by activating DCs, T-cells and by modulating immunosuppressive TME without systemic toxicity.